Abcellera Biologicsinc Stock Revenue
| ABCL Stock | USD 3.78 0.06 1.56% |
Abcellera BiologicsInc fundamentals help investors to digest information that contributes to Abcellera BiologicsInc's financial success or failures. It also enables traders to predict the movement of Abcellera Stock. The fundamental analysis module provides a way to measure Abcellera BiologicsInc's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Abcellera BiologicsInc stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 38 M | 36.1 M |
Abcellera | Revenue |
Abcellera BiologicsInc Company Revenue Analysis
Abcellera BiologicsInc's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Abcellera BiologicsInc Revenue | 38.02 M |
Most of Abcellera BiologicsInc's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Abcellera BiologicsInc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Abcellera
Projected quarterly revenue analysis of Abcellera BiologicsInc provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Abcellera BiologicsInc match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Abcellera BiologicsInc's stock price.
Abcellera Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Abcellera BiologicsInc is extremely important. It helps to project a fair market value of Abcellera Stock properly, considering its historical fundamentals such as Revenue. Since Abcellera BiologicsInc's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Abcellera BiologicsInc's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Abcellera BiologicsInc's interrelated accounts and indicators.
Click cells to compare fundamentals
Abcellera Revenue Historical Pattern
Today, most investors in Abcellera BiologicsInc Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Abcellera BiologicsInc's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Abcellera BiologicsInc revenue as a starting point in their analysis.
Abcellera BiologicsInc Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Abcellera Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Abcellera BiologicsInc reported 38.02 M of revenue. This is 99.5% lower than that of the Biotechnology sector and 94.88% lower than that of the Health Care industry. The revenue for all United States stocks is 99.6% higher than that of the company.
Abcellera Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Abcellera BiologicsInc's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Abcellera BiologicsInc could also be used in its relative valuation, which is a method of valuing Abcellera BiologicsInc by comparing valuation metrics of similar companies.Abcellera BiologicsInc is currently under evaluation in revenue category among related companies.
Abcellera BiologicsInc Institutional Holders
Institutional Holdings refers to the ownership stake in Abcellera BiologicsInc that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Abcellera BiologicsInc's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Abcellera BiologicsInc's value.| Shares | Casdin Capital, Llc | 2023-12-31 | 2.4 M | Fidelity International Ltd | 2023-12-31 | 1.9 M | Guardian Capital Advisors Lp | 2023-12-31 | 1.8 M | Prosight Management, Lp | 2023-12-31 | 1.7 M | Renaissance Technologies Corp | 2023-12-31 | 1.5 M | Millennium Management Llc | 2023-12-31 | 1.3 M | Goldman Sachs Group Inc | 2023-12-31 | 1.2 M | Novo A/s | 2023-12-31 | 1.1 M | Two Sigma Investments Llc | 2023-12-31 | 1.1 M | Baillie Gifford & Co Limited. | 2023-12-31 | 24 M | Baker Bros Advisors Lp | 2023-12-31 | 22.9 M |
Abcellera Fundamentals
| Return On Equity | -0.12 | ||||
| Return On Asset | -0.0979 | ||||
| Operating Margin | (7.20) % | ||||
| Current Valuation | 441.08 M | ||||
| Shares Outstanding | 292.78 M | ||||
| Shares Owned By Insiders | 28.08 % | ||||
| Shares Owned By Institutions | 43.62 % | ||||
| Number Of Shares Shorted | 23.09 M | ||||
| Price To Earning | 16.67 X | ||||
| Price To Book | 1.10 X | ||||
| Price To Sales | 33.42 X | ||||
| Revenue | 38.02 M | ||||
| Gross Profit | 311.11 M | ||||
| EBITDA | (192.16 M) | ||||
| Net Income | (146.4 M) | ||||
| Cash And Equivalents | 868.21 M | ||||
| Cash Per Share | 3.04 X | ||||
| Total Debt | 77.38 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 9.86 X | ||||
| Book Value Per Share | 3.96 X | ||||
| Cash Flow From Operations | (43.88 M) | ||||
| Short Ratio | 23.23 X | ||||
| Earnings Per Share | (0.51) X | ||||
| Price To Earnings To Growth | 2.22 X | ||||
| Target Price | 15.38 | ||||
| Number Of Employees | 586 | ||||
| Beta | 0.36 | ||||
| Market Capitalization | 1.12 B | ||||
| Total Asset | 1.49 B | ||||
| Retained Earnings | 279.79 M | ||||
| Working Capital | 752.97 M | ||||
| Net Asset | 1.49 B |
About Abcellera BiologicsInc Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Abcellera BiologicsInc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Abcellera BiologicsInc using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Abcellera BiologicsInc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Abcellera BiologicsInc
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abcellera BiologicsInc position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abcellera BiologicsInc will appreciate offsetting losses from the drop in the long position's value.Moving together with Abcellera Stock
| 0.86 | DVAX | Dynavax Technologies Financial Report 7th of May 2024 | PairCorr |
| 0.75 | EGRX | Eagle Pharmaceuticals | PairCorr |
| 0.75 | ELAN | Elanco Animal Health Financial Report 14th of May 2024 | PairCorr |
Moving against Abcellera Stock
| 0.8 | HCM | HUTCHMED DRC | PairCorr |
| 0.76 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.71 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.61 | FLGC | Flora Growth Corp Buyout Trend | PairCorr |
The ability to find closely correlated positions to Abcellera BiologicsInc could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abcellera BiologicsInc when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abcellera BiologicsInc - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abcellera BiologicsInc to buy it.
The correlation of Abcellera BiologicsInc is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abcellera BiologicsInc moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abcellera BiologicsInc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abcellera BiologicsInc can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Abcellera BiologicsInc Piotroski F Score and Abcellera BiologicsInc Altman Z Score analysis. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.Note that the Abcellera BiologicsInc information on this page should be used as a complementary analysis to other Abcellera BiologicsInc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Abcellera Stock analysis
When running Abcellera BiologicsInc's price analysis, check to measure Abcellera BiologicsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abcellera BiologicsInc is operating at the current time. Most of Abcellera BiologicsInc's value examination focuses on studying past and present price action to predict the probability of Abcellera BiologicsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abcellera BiologicsInc's price. Additionally, you may evaluate how the addition of Abcellera BiologicsInc to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is Abcellera BiologicsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera BiologicsInc. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera BiologicsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.459 | Earnings Share (0.51) | Revenue Per Share 0.131 | Quarterly Revenue Growth (0.57) | Return On Assets (0.1) |
The market value of Abcellera BiologicsInc is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera BiologicsInc's value that differs from its market value or its book value, called intrinsic value, which is Abcellera BiologicsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera BiologicsInc's market value can be influenced by many factors that don't directly affect Abcellera BiologicsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera BiologicsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera BiologicsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera BiologicsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.